ArticleBlood2026

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.

Tom van Meerten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.